Brand Reference: Vivelle-Dot, Climara, Dotti
| Metric | Verified Benchmark | Source |
|---|---|---|
| 17-Beta-Estradiol Transdermal Matrix System RxNorm Concept ID | 4083 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4.1800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $118.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $27.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $34.00 / mo | 41 Zero-PHI Verified Patient Logs |
Delivers bioidentical 17-beta-estradiol directly across dermal capillaries into systemic circulation—completely bypassing hepatic first-pass portal stimulation of clotting factors II/VII/X, angiotensinogen, triglycerides, and SHBG unlike oral conjugated equine estrogens.
CMS National Average Drug Acquisition Cost (NADAC) tracking places 17-Beta-Estradiol Transdermal Matrix System (Vivelle-Dot / Climara / Dotti, RxCUI 4083) at $4.1800 per unit, whereas walk-in chain pharmacies bill cash patients an average of $118.00 monthly—creating a 76% ($90.10/mo) wholesale arbitrage spread down to $27.90.
Systemic exposure to 17-Beta-Estradiol Transdermal Matrix System reflects Constant transdermal flux (25–100 mcg/24h) absorption kinetics and peripheral 17-beta-hsd interconversion with estrone and hepatic cyp1a2/3a4 hydroxylation, sustaining receptor engagement across a 16 hours skin depot decay post-removal half-life window (3–7 days vasomotor hot-flash suppression response profile).
Dosing protocols (0.025 mg/day patch twice weekly or 0.0375 mg/day twice weekly or 0.05 mg/day twice weekly or 0.075–0.1 mg/day twice weekly) balance efficacy (95.40% patient satisfaction across 41 logs) against transient breast tenderness (month 1) (19% of reports), adhesive patch erythema (16% of reports), spotting (11% of reports), with strict avoidance in active breast or endometrial carcinoma; active arterial or deep-vein thromboembolism; unexplained vaginal bleeding.
Across 41 verified cash-pay logs, 17-Beta-Estradiol Transdermal Matrix System achieves a 95.40% Worth-It rating with out-of-pocket spend averaging $34.00/mo versus $118.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.025 mg/day patch twice weekly for 17-Beta-Estradiol Transdermal Matrix System; monthly out-of-pocket dropped to $24.55 compared with $118.00 retail.
Completed 10 weeks on 17-Beta-Estradiol Transdermal Matrix System (0.0375 mg/day twice weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.05 mg/day twice weekly 17-Beta-Estradiol Transdermal Matrix System sourced via Cost Plus Drugs ($32.36/mo cash pay without insurance prior authorization).